RVTY

Revvity Inc

Feb 02 • 04:00PM ET

107.09

-1.71 -1.57 %

Healthcare • Diagnostics & Research • USA • NYSE

Feb 02, 12:32 PMRevvity reports fiscal Q4 2025 results with non-GAAP EPS $1.70 (+20% YoY) and revenue $772.1M (+6% YoY), beating EPS and revenue estimates, and issues 2026 guidance for $2.96–$2.99B revenue and $5.35–$5.45 non-GAAP EPS.

Peers: TMO DHR A MTD BIO WAT BRKR ILMN

| Held by: VTI VOO VB RSP VBR IVV SPY TCAF XLV IWR

Scroll to Statements

Index	S&P 500	P/E	51.84	EPS (ttm)	2.07	Insider Own	0.45%	Shs Outstand	113.38M	Perf Week	-6.63%
Market Cap	12.14B	Forward P/E	17.93	EPS next Y	5.97	Insider Trans	-0.10%	Shs Float	112.86M	Perf Month	10.69%
Enterprise Value	14.59B	PEG	2.02	EPS next Q	1.04	Inst Own	103.44%	Short Float	6.14%	Perf Quarter	17.66%
Income	239.21M	P/S	4.25	EPS this Y	6.62%	Inst Trans	-0.27%	Short Ratio	4.70	Perf Half Y	21.38%
Sales	2.86B	P/B	1.66	EPS next Y	10.72%	ROA	1.95%	Short Interest	6.93M	Perf YTD	10.69%
Book/sh	64.68	P/C	13.20	EPS next 5Y	8.87%	ROE	3.21%	52W High	128.04 -16.36%	Perf Year	-15.57%
Cash/sh	8.11	P/FCF	23.89	EPS past 3/5Y	-22.97% -20.54%	ROIC	2.38%	52W Low	81.36 31.62%	Perf 3Y	-20.65%
Dividend Est.	0.28 (0.26%)	EV/EBITDA	18.22	Sales past 3/5Y	-4.82% -5.47%	Gross Margin	46.74%	Volatility	3.93% 3.83%	Perf 5Y	-26.77%
Dividend TTM	0.28 (0.26%)	EV/Sales	5.11	EPS Y/Y TTM	-18.80%	Oper. Margin	13.84%	ATR (14)	3.89	Perf 10Y	121.31%
Dividend Ex-Date	Apr 17, 2026	Quick Ratio	1.40	Sales Y/Y TTM	3.67%	Profit Margin	8.38%	RSI (14)	48.48	Recom	2.36
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	1.68	EPS Q/Q	8.45%	SMA20	-2.53%	Beta	1.09	Target Price	117.38
Payout	13.61%	Debt/Eq	0.46	Sales Q/Q	5.85%	SMA50	3.40%	Rel Volume	2.23	Prev Close	108.80
Employees	11000	LT Debt/Eq	0.38	Earnings	Feb 02 BMO	SMA200	12.63%	Avg Volume	1.47M	Price	107.09
IPO	Jul 06, 1965	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.29% 0.93%	Trades		Volume	3,217,527	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Downgrade	BofA Securities	Buy → Neutral	$110
Dec-09-25	Initiated	Goldman	Neutral	$105
Oct-16-25	Initiated	Guggenheim	Neutral
May-01-25	Upgrade	UBS	Neutral → Buy	$115
Jan-10-25	Downgrade	Bernstein	Outperform → Mkt Perform	$130
Dec-13-24	Upgrade	BofA Securities	Neutral → Buy	$138
Oct-15-24	Upgrade	Barclays	Equal Weight → Overweight	$125 → $140
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$130
Jul-08-24	Initiated	Leerink Partners	Outperform	$125
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	UBS	Buy → Neutral	$105 → $125
Jan-04-24	Upgrade	Evercore ISI	In-line → Outperform	$88 → $125
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$95
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Sep-28-23	Initiated	Bernstein	Outperform	$133
Jul-19-23	Initiated	Raymond James	Outperform	$145
May-23-23	Resumed	Goldman	Buy	$150

Show Previous Ratings

Feb-02-26 02:01PM	Revvity Inc (RVTY) Q4 2025 Earnings Call Highlights: Surpassing EPS Guidance and Strategic ... (GuruFocus.com)
12:52PM	Revvity Q4 Earnings Call Highlights (MarketBeat)
12:44PM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:28AM	Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers (Benzinga)
10:06AM	Do Options Traders Know Something About Revvity Stock We Don't? (Zacks)
09:49AM	Loading…
09:49AM	Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates (Zacks)
09:30AM	Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:15AM	Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:29AM	Revvity's (NYSE:RVTY) Q4 CY2025 Sales Beat Estimates (StockStory)
06:21AM	Revvity: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025 (Business Wire)
Jan-31-26 10:01PM	Revvity (RVTY) Q4 Earnings: What To Expect (StockStory)
Jan-29-26 12:51PM	Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery? (Zacks)
Jan-28-26 09:15AM	Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
07:10AM	Elevance Health (ELV) Beats Q4 Earnings Estimates (Zacks)
04:05PM	Loading…
Jan-26-26 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
10:00AM	Revvity (RVTY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-23-26 12:10PM	Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-21-26 07:58AM	Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (Zacks)
Jan-14-26 06:07AM	Revvity Stock Gains On Solid Early Q4 Results, Upbeat Outlook (Benzinga)
Jan-13-26 06:43PM	Analyst Report: Revvity, Inc. (Morningstar Research) +6.02%
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
10:14AM	These Stocks Are Todays Movers: JPMorgan, Delta, Intel, AMD, L3Harris, Travere, Revvity, and More (Barrons.com)
09:42AM	Stocks to Watch Tuesday: JPMorgan, Delta, L3Harris (The Wall Street Journal)
05:51AM	Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads. (Barrons.com)
05:28AM	Stock Market Today: S&P 500, Dow Jones Futures Slip Ahead Of December CPI Print- JPMorgan, Alphabet, Five9 In Focus (Benzinga)
Jan-12-26 04:15PM	Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance (Business Wire)
08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-09-26 08:00AM	Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models (Business Wire)
04:51AM	Loading…
Jan-05-26 04:51AM	What to Expect From Revvitys Q4 2025 Earnings Report (Barchart)
Dec-31-25 07:39AM	Here's Why Diamond Hill Mid Cap Composite Purchased Revvity (RVTY) in Q3 (Insider Monkey)
Dec-22-25 10:37PM	Q3 Earnings Highlights: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
Dec-19-25 08:41AM	Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica (Zacks)
Dec-18-25 08:00AM	Revvity to Present at J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 11:04PM	3 Reasons RVTY is Risky and 1 Stock to Buy Instead (StockStory)
Dec-16-25 08:00AM	Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery (Business Wire)
Dec-15-25 06:30AM	How Is Revvity's Stock Performance Compared to Other Health Care Stocks? (Barchart)
Dec-09-25 08:16AM	Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy (Investing.com)
Nov-26-25 11:30AM	Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-19-25 08:35AM	Revvity Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-10-25 07:45AM	Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities (Business Wire)
Nov-03-25 12:31AM	5 Insightful Analyst Questions From Revvity's Q3 Earnings Call (StockStory)
Oct-28-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
06:17AM	Company News for Oct 28, 2025 (Zacks)
01:31AM	RVTY Q3 Deep Dive: AI Initiatives and Segment Divergence Shape Outlook (StockStory)
Oct-27-25 03:00PM	Revvity Inc (RVTY) Q3 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... (GuruFocus.com)
01:22PM	Analyst Report: Revvity, Inc. (Morningstar Research)
01:10PM	Revvity (RVTY) Stock Trades Down, Here Is Why (StockStory)
10:05AM	RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised (Zacks)
09:30AM	Revvity (RVTY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:10AM	Revvity (RVTY) Surpasses Q3 Earnings Estimates (Zacks)
06:18AM	Revvity (NYSE:RVTY) Posts Q3 Sales In Line With Estimates (StockStory)
06:09AM	Revvity: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Third Quarter of 2025 (Business Wire)
Oct-25-25 11:02PM	Revvity (RVTY) Q3 Earnings Report Preview: What To Look For (StockStory)
Oct-23-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
07:53AM	Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand? (Zacks)
Oct-22-25 09:15AM	Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Oct-21-25 10:00AM	Labcorp Holdings (LH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-20-25 10:00AM	Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-16-25 02:40AM	Here's What to Expect From Revvity's Next Earnings Report (Barchart)
Oct-14-25 11:35PM	Research Tools & Consumables Stocks Q2 Teardown: Revvity (NYSE:RVTY) Vs The Rest (StockStory)
08:00AM	Revvity Showcases Progress with Purpose in 2025 Impact Report (Business Wire)
Oct-13-25 11:38AM	Analyst Report: Revvity, Inc. (Morningstar Research)
Oct-09-25 11:55AM	RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes (Zacks)
Oct-06-25 08:00AM	Revvity to Hold Earnings Call on Monday, October 27, 2025 (Business Wire)
Oct-02-25 08:00AM	Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes (Business Wire)
Sep-29-25 08:00AM	Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis (Business Wire)
Sep-23-25 02:26PM	Revvity Stock: Is RVTY Underperforming the Healthcare Sector? (Barchart)
Sep-22-25 08:00AM	Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems (Business Wire)
Sep-12-25 12:35AM	1 Oversold Stock Primed to Rebound and 2 We Brush Off (StockStory)
Sep-10-25 04:53AM	Revvity, Inc. (RVTY) Launches its New In Vivo Imaging Center of Excellence (Insider Monkey)
Sep-03-25 12:36PM	Revvity (RVTY) Stock Trades Down, Here Is Why (StockStory) -5.13%
Sep-02-25 02:26PM	Why Revvity (RVTY) Stock Is Trading Lower Today (StockStory)
08:00AM	Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina (Business Wire)
Aug-27-25 04:32PM	Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution (PR Newswire)
Aug-18-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
12:02AM	3 Reasons to Sell RVTY and 1 Stock to Buy Instead (StockStory)
Aug-13-25 12:23AM	The Top 5 Analyst Questions From Revvity's Q2 Earnings Call (StockStory)
12:21AM	RVTY Q2 Deep Dive: China Diagnostics Headwinds Offset Life Sciences Stability (StockStory)
Aug-12-25 02:20PM	Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know (StockStory)
Aug-06-25 08:00AM	Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics (Business Wire)
Jul-30-25 09:25AM	Revvity price target lowered to $110 from $120 at Stifel (TipRanks)
Jul-29-25 03:02AM	Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... (GuruFocus.com)
Jul-28-25 02:15PM	Why Revvity (RVTY) Stock Is Falling Today (StockStory) -8.32%
11:51AM	Revvity Slashes Outlook As China Policy Deals Diagnostics Blow (Benzinga)
11:51AM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:11AM	RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View (Zacks)
09:30AM	Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:39AM	Revvity Stock Tumbles After Earnings. What's Dragging on the Shares. (Barrons.com)
07:10AM	Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:26AM	Revvity (NYSE:RVTY) Surprises With Q2 Sales (StockStory)
06:07AM	Revvity: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Second Quarter of 2025 (Business Wire)
Jul-26-25 11:04PM	What To Expect From Revvity's (RVTY) Q2 Earnings (StockStory)
Jul-25-25 12:10PM	Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-24-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
11:11AM	Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat? (Zacks)
Jul-23-25 09:15AM	Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings (Zacks)

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vohra Tajinder S	Officer	Feb 02 '26	Proposed Sale	104.50	5,756	601,502		Feb 02 10:57 AM
MICHAS ALEXIS P	Director	Aug 27 '25	Sale	89.01	500	44,505	7,270	Aug 28 04:05 PM
MICHAS ALEXIS P	Officer	Aug 27 '25	Proposed Sale	88.00	500	44,000		Aug 27 03:29 PM
McMurry-Heath Michelle	Director	May 29 '25	Sale	92.17	600	55,299	4,833	May 30 04:06 PM
McMurry-Heath Michelle	Director	May 29 '25	Proposed Sale	92.17	600	55,299		May 29 02:23 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Sale	119.49	1,970	235,395	3,021	Feb 07 04:05 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Proposed Sale	119.49	1,970	235,395		Feb 06 03:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVTY

Revvity Inc

Upgrade your FINVIZ experience